Thomas P Madaelil1, Adam N Wallace2, Jack W Jennings2. 1. Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, St Louis, MO, 63110, USA. madaelilt@mir.wustl.edu. 2. Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, St Louis, MO, 63110, USA.
Abstract
PURPOSE: To determine the safety and effectiveness of radiofrequency ablation (RFA) to treat sacral metastases for pain palliation and local tumor control (LTC). MATERIALS AND METHODS: An institutional tumor ablation registry was retrospectively reviewed for sacral RFA procedures performed between January 2012 and December 2015. Clinical history, pre-procedural imaging, and procedural details were reviewed to document indication for treatment, primary tumor histology, tumor volumes, presence of concurrent cementoplasty after RFA, and the occurrence of peri-procedural complications. Pain scores before and 4 weeks after the procedure were recorded. Post-procedure imaging was reviewed for imaging evidence of tumor progression. Long-term complications and duration of clinical follow-up were recorded. RESULTS: During the study period, 11 RFA procedures were performed to treat 16 sacral metastases. All procedures were for pain palliation. Four procedures (36 %; 4 out of 11) were also performed with the intention of achieving LTC in patients with oligometastatic disease. Concurrent cementoplasty was performed in 63 % of cases (7 out of 11). The median pain score decreased from 8 (interquartile range, 6-9.25) at baseline to 3 (interquartile range, 1.75-6.3) 1 month following RFA (P = 0.004). In the 4 patients with oligometastatic disease, LTC was achieved in 3 patients (75 %; 3 out of 4) after a median follow-up of 7.6 months (range, 3.6-11.9 months). No acute or long-term complications were documented during the overall median clinical follow-up of 4.7 months (range, 0.9-28.7 months). CONCLUSIONS: Radiofrequency ablation maybe a safe and potentially effective treatment for patients with painful sacral metastases and can achieve LTC in selected patients.
PURPOSE: To determine the safety and effectiveness of radiofrequency ablation (RFA) to treat sacral metastases for pain palliation and local tumor control (LTC). MATERIALS AND METHODS: An institutional tumor ablation registry was retrospectively reviewed for sacral RFA procedures performed between January 2012 and December 2015. Clinical history, pre-procedural imaging, and procedural details were reviewed to document indication for treatment, primary tumor histology, tumor volumes, presence of concurrent cementoplasty after RFA, and the occurrence of peri-procedural complications. Pain scores before and 4 weeks after the procedure were recorded. Post-procedure imaging was reviewed for imaging evidence of tumor progression. Long-term complications and duration of clinical follow-up were recorded. RESULTS: During the study period, 11 RFA procedures were performed to treat 16 sacral metastases. All procedures were for pain palliation. Four procedures (36 %; 4 out of 11) were also performed with the intention of achieving LTC in patients with oligometastatic disease. Concurrent cementoplasty was performed in 63 % of cases (7 out of 11). The median pain score decreased from 8 (interquartile range, 6-9.25) at baseline to 3 (interquartile range, 1.75-6.3) 1 month following RFA (P = 0.004). In the 4 patients with oligometastatic disease, LTC was achieved in 3 patients (75 %; 3 out of 4) after a median follow-up of 7.6 months (range, 3.6-11.9 months). No acute or long-term complications were documented during the overall median clinical follow-up of 4.7 months (range, 0.9-28.7 months). CONCLUSIONS: Radiofrequency ablation maybe a safe and potentially effective treatment for patients with painful sacral metastases and can achieve LTC in selected patients.
Authors: Nelson Moussazadeh; Ilya Laufer; Timothy Werner; George Krol; Patrick Boland; Mark H Bilsky; Eric Lis Journal: Neurosurgery Date: 2015-04 Impact factor: 4.654
Authors: Atif J Khan; Par S Mehta; Thomas W Zusag; Philip D Bonomi; L Penfield Faber; Susan Shott; Ross A Abrams Journal: Radiother Oncol Date: 2006-10-16 Impact factor: 6.280
Authors: Brendan P McMenomy; A Nicholas Kurup; Geoffrey B Johnson; Rickey E Carter; Robert R McWilliams; Svetomir N Markovic; Thomas D Atwell; Grant D Schmit; Jonathan M Morris; David A Woodrum; Adam J Weisbrod; Peter S Rose; Matthew R Callstrom Journal: J Vasc Interv Radiol Date: 2012-12-20 Impact factor: 3.464
Authors: Ning Mao Kam; Julian Maingard; Hong Kuan Kok; Dinesh Ranatunga; Duncan Brooks; William C Torreggiani; Peter L Munk; Michael J Lee; Ronil V Chandra; Hamed Asadi Journal: Curr Treat Options Oncol Date: 2017-11-16
Authors: Caroline A Burgard; Julien Dinkel; Frederik Strobl; Philipp M Paprottka; Nicolai Schramm; Maximilian Reiser; Christoph G Trumm Journal: Diagn Interv Radiol Date: 2018 May-Jun Impact factor: 2.630